A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 2002 participants.

Also called NCT03730662

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 2,002 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03730662
  • EudraCT 2018-002618-11
Other papers using this trial's data
  • Effects of tirzepatide versus insulin glargine on kidney outcomes in type 2 diabetes in the SURPASS-4 trial: post-hoc analysis of an open-label, randomised, phase 3 trial The lancet. Diabetes & endocrinology, 2022-11 DOI, PubMed 36152639
  • Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial Lancet (London, England), 2021-11-13 DOI, PubMed 34672967

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Australia, Brazil, Canada, Greece, Israel, Mexico, Poland, Puerto Rico, Romania, Russia, Slovakia, Spain, Taiwan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03730662. Randomized; no masking; primary purpose treatment. Start 2018-11-20 (actual); primary completion 2021-01-22 (actual). Results posted on 2022-02-14.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of Tirzepatide (LY3298176) Once a Week Versus Insulin Glargine Once a Day in Participants With Type 2 Diabetes and Increased Cardiovascular Risk
Acronym
SURPASS-4
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Tirzepatide
Intervention (Drug)
Insulin Glargine
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct03730662
Content hash
15b87af8fe3d30cab4a71084121eefc2647ff2e236e2e3eefed2cc80e86a2ceb